Afamelanotide
Evidence: A — Established Human EvidenceDermatology / Cosmetic Research
Evidence Snapshot
What this grade covers
A for FDA-approved SCENESSE identity, adult EPP indication, label efficacy, and label safety (also EMA-authorized for the same indication); B/C for selected off-label dermatology trials (e.g. vitiligo phototherapy combination); D/E for cosmetic tanning, compounded-product equivalence, nonimplant routes, anti-aging, or consumer-use claims; ORPHAN/DEVELOPMENT STATUS ONLY (not an approved indication or proven efficacy) for the 2025 pemphigus orphan drug designation.
Regulatory Context
SCENESSE is FDA-approved as a controlled-release implant to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. The approval does not extend to unregulated powders, injections, nasal products, or cosmetic tanning use sold under Afamelanotide, Melanotan I, or similar names.
Research Takeaway
Afamelanotide is a synthetic alpha-melanocyte-stimulating-hormone analog and melanocortin-1 receptor agonist; historical 'Melanotan I' terminology must not be conflated with Melanotan II, which is a distinct cyclic melanocortin analog.
Evidence boundary: Shared pigmentation biology does not establish identity or therapeutic interchangeability with Melanotan II.
See all 10 evidence claims →Quick Summary
Afamelanotide is a synthetic melanocortin-1 receptor agonist with an FDA-approved controlled-release implant for adults with erythropoietic protoporphyria. Randomized trials support increased pain-free light exposure in that narrow indication. The approved implant, clinical monitoring, and manufacturing controls should not be equated with unregulated products marketed for cosmetic tanning.
Mechanism & Research Overview
Afamelanotide binds predominantly to melanocortin-1 receptors and increases eumelanin production independently of ultraviolet exposure. In EPP, the clinical goal is to increase the amount of light exposure patients can tolerate without phototoxic pain. This mechanism and the approved implant evidence do not establish safety or benefit for cosmetic tanning products.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Afamelanotide is a synthetic alpha-melanocyte-stimulating-hormone analog and melanocortin-1 receptor agonist; historical 'Melanotan I' terminology must not be conflated with Melanotan II, which is a distinct cyclic melanocortin analog.
Does not establish
Evidence boundary: Shared pigmentation biology does not establish identity or therapeutic interchangeability with Melanotan II.
Sources: SCENESSE (afamelanotide) Prescribing Information (2019 initial approval label)
Supported
Scenesse (afamelanotide) is FDA-approved to increase pain-free light exposure in adults with erythropoietic protoporphyria and a history of phototoxic reactions.
Does not establish
Evidence boundary: This approval does not establish a cosmetic tanning indication.
Sources: SCENESSE (afamelanotide) Prescribing Information (2019 initial approval label); FDA approval letter for Scenesse (afamelanotide) implant; FDA Orphan Drug Approval Record for Afamelanotide in Erythropoietic Protoporphyria
Supported
Randomized human trials in erythropoietic protoporphyria demonstrate increased tolerated light exposure and improvement in patient-reported quality-of-life measures with afamelanotide.
Does not establish
Evidence boundary: EPP photoprotection cannot be generalized to cosmetic tanning, anti-aging, or universal photoprotection.
Supported
Approved afamelanotide use requires attention to implant-related and pigmentation-related safety monitoring defined in the product labeling.
Does not establish
Evidence boundary: The approved safety profile applies to the reviewed implant product and clinical use, not unregulated melanocortin preparations.
Sources: SCENESSE (afamelanotide) Prescribing Information (2019 initial approval label)
Supported
Evidence supporting Scenesse does not establish that Melanotan II or an unapproved product marketed as 'Melanotan I' is therapeutically equivalent to FDA-approved afamelanotide implant.
Does not establish
Evidence boundary: Molecular relationship or marketing terminology is not evidence of finished-product equivalence.
Sources: SCENESSE (afamelanotide) Prescribing Information (2019 initial approval label)
Supported
Only dosing and administration from the FDA-approved Scenesse label or a named clinical trial may appear as Study/Trial Dosing; no consumer tanning or self-administration protocol may be provided.
Does not establish
Evidence boundary: Approved implant administration is a healthcare-professional treatment context, not consumer guidance.
Sources: SCENESSE (afamelanotide) Prescribing Information (2019 initial approval label)
Supported
Long-term real-world observational studies report improved outcomes with afamelanotide in erythropoietic protoporphyria clinical practice, consistent with the pivotal randomized trial findings.
Sources: Long-Term Observational Study of Afamelanotide in EPP
Supported
Scenesse (afamelanotide) also holds European Medicines Agency marketing authorization for the same erythropoietic protoporphyria indication.
Supported
Separate randomized and phototherapy-combination trials have studied afamelanotide combined with narrowband UV-B phototherapy for vitiligo repigmentation, an indication outside the FDA-approved erythropoietic protoporphyria use; this off-label vitiligo evidence does not establish an approved vitiligo indication or the same efficacy and safety profile as the approved EPP use.
Sources: Afamelanotide and narrowband UV-B phototherapy for vitiligo; Afamelanotide Plus NB-UVB for Nonsegmental Vitiligo in Asians
Supported
FDA granted afamelanotide orphan drug designation for pemphigus in 2025; this is a development-program status only and does not represent an approved indication, established efficacy, or an FDA-approved pemphigus treatment.
Sources: FDA Orphan Designation for Afamelanotide in Pemphigus
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
The current label reports serious hypersensitivity reactions including anaphylaxis and gives product-specific management requirements.Safety Consideration
Generalized pigmentation and darkening of pre-existing nevi or ephelides may occur; the label recommends regular full-body skin examinations.Safety Consideration
The approved label directs continued protection against EPP-related phototoxicity during treatment.Safety Consideration
Unregulated products may differ in identity, dose delivery, formulation, sterility, purity, release characteristics, and monitoring.Safety Consideration
EPP trial results do not establish general cosmetic tanning, melanoma prevention, or broad photoprotection in healthy people.Safety Consideration
FDA required long-term postmarketing surveillance for melanoma and nonmelanoma skin cancer, implant-site reactions, pigmentary changes, pregnancy outcomes, lactation exposure, and implant-device malfunction or failure -- these requirements identify uncertainties requiring long-term study rather than proving the risks occur. Additional label gaps: pregnancy data are inadequate, lactation data are absent, pediatric safety/efficacy are not established, renal/hepatic effects on pharmacokinetics are unknown, no drug-interaction studies were conducted, carcinogenicity studies were not conducted, and metabolism was not fully characterized. Implant expulsion or device/implantation complications can also occur.
Research Areas Being Studied
Research areas discussed on this page reflect the Dermatology / Cosmetic Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| SCENESSE (afamelanotide) Prescribing Information (2019 initial approval label) | 2019 | The initial 2019 SCENESSE prescribing information summarizes two vehicle-controlled EPP trials: Study CUV039 (93 subjects) reported median pain-free direct-sunlight time over 180 days of 64.1 hours with SCENESSE versus 40.5 hours with vehicle; Study CUV029 (74 subjects) reported 6.0 hours versus 0.75 hours under a narrower recording definition. The label lists common adverse reactions (implant-site reactions, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory-tract infection, skin irritation), recommends twice-yearly full-body skin examinations, and states that pregnancy data are inadequate, lactation data are absent, pediatric safety/efficacy are not established, renal/hepatic pharmacokinetic effects are unknown, no drug-interaction studies were conducted, and carcinogenicity studies were not conducted. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Afamelanotide’s high evidence grade applies only to the exact approved SCENESSE implant and adult EPP indication. It does not validate cosmetic tanning, unsupervised ultraviolet exposure, or gray-market products.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-07-30.
Follow research updates for Afamelanotide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.